• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Wockhardt Ltd.
    04 Jun 2025
    1493.70
    2.27%
    Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala
    Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala
    NDTV Profit
    In FY25, the company's revenue stood at Rs 3,012 crore, compared to Rs 2,798 crore in FY24.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. is trading above its 200 day SMA of 1461.0
    logo
    Alkem Laboratories Ltd.
    03 Jun 2025
    5336.00
    0.06%
    Alkem Promoter Jayanti Sinha To Sell 1.42% Stake Via Block Deal
    Alkem Promoter Jayanti Sinha To Sell 1.42% Stake Via Block Deal
    NDTV Profit
    The floor price for the shares has been set at Rs 4,850 apiece, a discount of about 3% to Alkem's current market price.
    Copy LinkShare onShare on Share on Share on
    Alkem Laboratories L.. has an average target of 5296.00 from 2 brokers.
    logo
    Indoco Remedies Ltd.
    03 Jun 2025
    276.70
    -0.11%
    Indoco Remedies Subsidiary Launches Generic Drug In UK
    Indoco Remedies Subsidiary Launches Generic Drug In UK
    NDTV Profit
    This significant addition to Indo Remedies portfolio will be marketed and distributed by Clarity Pharma across the UK, it added.
    Copy LinkShare onShare on Share on Share on
    Indoco Remedies Ltd. is trading below all available SMAs
    logo
    Biocon Ltd.
    03 Jun 2025
    364.50
    0.10%
    Biocon Gets CDSCO Nod For Generic Diabetes Medication
    Biocon Gets CDSCO Nod For Generic Diabetes Medication
    NDTV Profit
    The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above.
    Copy LinkShare onShare on Share on Share on
    Biocon Ltd. is trading above its 200 day SMA of 353.6
    Biocon gets CDSCO approval for generic diabetes medication 'Liraglutide'
    Business Standard | 03 Jun 2025 1 more
    Biocon share price pops 2% on CDSCO nod for diabetes drug; key details here
    Business Standard | 03 Jun 2025
    logo
    Dr. Reddy's Laboratories Ltd.
    02 Jun 2025
    US FDA Observation
    1291.30
    3.25%
    A test case' unfolds over Novo Nordisk's weight loss and diabetes drug semaglutide
    Business Line
    Novo Nordisk is locked in a patent infringement battle with Dr Reddy's Laboratories and OneSource Specialty Pharma
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laboratories Ltd. is trading above all available SMAs
    logo
    AstraZeneca Pharma India Ltd.
    02 Jun 2025
    9100.50
    0.61%
    AstraZeneca Pharma shares surge 12% after Q4 results; profit jumps 48%
    Business Standard
    AstraZeneca Pharma India rallied nearly 12 per cent after its net profit for the fourth quarter of the previous financial year jumped 48 per cent
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading above all available SMAs
    AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth
    NDTV Profit | 02 Jun 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    02 Jun 2025
    1591.70
    0.68%
    New launches to drive Sun Pharma's future growth; PAT may take a hit by tax surge
    New launches to drive Sun Pharma's future growth; PAT may take a hit by tax surge
    Economic Times
    Sun Pharma anticipates revenue growth for fiscal year 26, building on an 8% increase in fiscal year 25. However, increased spending on marketing specialty products may impact profitability. Net profit declined in the March quarter due to higher taxes. The company plans to launch new drugs like Leqselvi and Unloxcyt.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    Sun Pharma Lines Up $100 Million To Commercialise Niche Products This Fiscal
    NDTV Profit | 01 Jun 2025 2 more
    Sun Pharma to invest $100 mn in commercialising speciality products this fiscal
    Business Line | 01 Jun 2025
    Sun Pharma lines up $100 mn to commercialise niche products in FY26
    Business Standard | 01 Jun 2025
    logo
    Ipca Laboratories Ltd.
    01 Jun 2025
    1320.10
    -0.02%
    Ipca Labs Q4 Results Review: Dolat Capital Maintains 'Add', Revises Target Price
    Ipca Labs Q4 Results Review: Dolat Capital Maintains 'Add', Revises Target Price
    NDTV Profit
    Dolat Capital maintains Accumulate' rating at 30x FY27E P/E with a revised target price of Rs 1,604.
    Copy LinkShare onShare on Share on Share on
    Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.
    logo
    Dr. Reddy's Laboratories Ltd.
    31 May 2025
    US FDA Observation
    1291.30
    3.25%
    Dr Reddy's faces 2,395 crore tax demand
    Business Line
    Disputes reassessment linked to merger under amalgamation scheme
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laboratories Ltd. is trading above all available SMAs
    logo
    Pfizer Ltd.
    31 May 2025
    5153.00
    0.18%
    Breast cancer: Pfizer-Arvinas drug beats AstraZeneca's in delaying disease's progression
    Business Line
    Trial finds Pfizer and Arvinas' experimental drug vepdegestrant increases survival without progression of breast cancer in patients with ESR1 mutations by five months
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 129 to 139 in Jun 2025 qtr.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd